| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
The following is a roundup of top developments in the biotech space over the last 24 hours.
(Biotech stocks that hit 52-week highs Sept. 23.)
(Biotech stocks that hit 52-week lows Sept. 23)
Novartis AG (NYSE:NVS)'s Sandoz unit said it is voluntarily recalling all quantities and lots of ranitidine hydrochloride capsules in the U.S. to the consumer levels due to confirmed contamination with N-Nitrosodimethylamine, or NDMA, above the levels established by the FDA.
NDMA is considered a probable carcinogen based on lab tests.
Ranitidine hydrochloride capsules are an oral product indicated to treat ulcers.
To date, the company said it has not received any reports of adverse events related to use of the product as part of this recall.
See also: The Week Ahead In Biotech: Spotlight On ESMO Conference
ANCHIANO THERAP/S ADR (NASDAQ:ANCN) said its U.S. subsidiary has entered into an exclusive worldwide collaboration and option to license agreement with ADT Pharma to develop novel small-molecule inhibitors of RAS and PDE10/β-catenin.
Under the terms of the agreement, Anchiano will be granted an exclusive option to license the RAS and PDE10/β-catenin inhibitors in exchange for a $3-million upfront payment.
Anchiano will have the option to exclusively license the compounds worldwide at any time by obtaining an IND designation.
If Anchiano exercises its option, it will be responsible for development and commercialization and will incur additional payment obligations, including milestone and royalty payments to ADT.
The stock gained 6.74% to $2.85 in after-hours trading.
Proteon Therapeutics Inc (NASDAQ:PRTO), which focuses on treatments for kidney and vascular diseases, announced an agreement to merge with privately held biopharma ArTara Therapeutics, which develops treatments for rare and specialty diseases.
The merged company will focus on advancing ArTara's pipeline of transformative late-stage, de-risked, rare and specialty disease assets. Upon stockholder approval, the combined company is expected to operate under the name ArTara Therapeutics, Inc. and trade on the Nasdaq Capital Market under the ticker symbol "TARA."
The stock rallied 18.98% to 40 cents in after-hours trading.
German pharma company Evotec SE (OTC:EVTCY) and Japan's Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced a strategic, multiyear drug discovery collaboration, under which the companies aim to establish at least five drug discovery programs. Evotec will deliver clinical candidates for Takeda to pursue into clinical development.
Under the terms, Takeda will pay Evotec a one-time, upfront fee to access its platforms. Additionally, Evotec is eligible to receive pre-clinical, clinical and commercial milestones that can total in excess of $170 million per program as well as tiered royalties on future sales.
Urogen Pharma Ltd (NASDAQ:URGN) will present initial Phase 2b data for its UGN-102 in low-grade, non-muscle invasive bladder cancer.
Related Link: Axsome Shares Flirt With Record High: How Much Upside Is Left?
Posted In: ADRO AEZS AKCA ANCN APLT AVDL BASI BIO BNGO CBIO CELG CLLS CLVS DRRX ENLV ERYP EVTCY IBB KALV KOOL
